Indoma Launches in Dubai, Set to Bring Intensive Neurorehabilitation Care into Patients’ Own Homes
(MENAFN- ruderfinn atteline) Dubai, UAE – 12 October 2026: Indoma, a U.S.-based specialized neurorehabilitation company, has launched operations in Dubai, marking the next stage of its international expansion. Indoma’s model is grounded in neuroplasticity, the brain’s capacity to adapt and relearn after injury, and the evidence that meaningful gains remain possible for many patients even after progress is often assumed to stop.
After launching its first international clinical program in Santiago, Chile in 2025, Indoma will bring its intensive technology-augmented model to the UAE for people recovering from stroke, mild traumatic brain injury (mTBI), and other neurological events. In specific conditions such as Parkinson’s Disease and Multiple Sclerosis, Indoma deploys similar cutting-edge technologies to maintain and improve neuromuscular and cognitive function.
Following a physician-led assessment, Indoma brings together medical oversight, multidisciplinary rehabilitation, and dedicated care coordination within one personalized plan, focusing on repetition, progression, and ongoing clinical review for suitable patients. Indoma delivers the sustained, high-intensity therapy of a specialist rehabilitation program in the patient’s own environment, using breakthrough technologies to maximize each person’s recovery potential.
Oren Schneider, Co-founder and Chief Executive Officer of Indoma, said, “Hospital discharge is a milestone, not the end of the rehabilitation journey. That conviction is reflected in our name, drawing on the word ‘indomitable’ and the determination to keep moving forward in the face of adversity. We built Indoma to give patients and families a clear path forward when the next step is uncertain. Our focus on patient care drives us to look towards the future of medical technologies as well as to offer each patient the most appropriate and effective treatment currently available - the UAE’s record of translating ambition into action makes it a natural place for the next stage of our growth.”
Dr. Teo Forcht Dagi, Neurosurgeon, and Chairman and Chief Medical Officer of Indoma, said, “The science of neuroplasticity shows that the brain's capacity to recover is not fixed, but can be activated and enhanced by high-frequency, high-intensity, repetitive input and consistent delivery - provided therapy is delivered at sufficient intensity and duration. Each element of Indoma’s practice demonstrates our role in harnessing a patient’s neuroplasticity: the intensity of therapy, the technologies we select, the home setting, the holistic support, and the duration of care. In the UAE, we intend to work as colleagues to the neurologists, neurosurgeons, and rehabilitation physicians already caring for these patients, and to uphold ourselves to the clinical governance expected of any academic center.”
Leading clinical delivery in Dubai will be Dr. Nazakat Hussain, Indoma’s UAE Medical Director, a locally based Consultant in Physical Medicine and Rehabilitation with over 30 years of experience across the UK and UAE, while also serving as Director of the Spinal Cord Injury Program and Clinical Lead for Neurorehabilitation at Specialized Rehabilitation Hospital (SRH) in Abu Dhabi. Joining him will be Dr. Dagi, who holds appointments as Professor of Neurosurgery at the Mayo Clinic College of Medicine and Science, and provides global medical leadership and clinical governance across all Indoma markets.
Indoma will complement the country’s existing healthcare ecosystem by building clinical and referral relationships with physicians, hospitals, and rehabilitation partners, while working alongside the medical teams that patients already know and trust. The service will begin accepting patients through referral or by direct enquiry in the coming weeks.
-ENDS-
After launching its first international clinical program in Santiago, Chile in 2025, Indoma will bring its intensive technology-augmented model to the UAE for people recovering from stroke, mild traumatic brain injury (mTBI), and other neurological events. In specific conditions such as Parkinson’s Disease and Multiple Sclerosis, Indoma deploys similar cutting-edge technologies to maintain and improve neuromuscular and cognitive function.
Following a physician-led assessment, Indoma brings together medical oversight, multidisciplinary rehabilitation, and dedicated care coordination within one personalized plan, focusing on repetition, progression, and ongoing clinical review for suitable patients. Indoma delivers the sustained, high-intensity therapy of a specialist rehabilitation program in the patient’s own environment, using breakthrough technologies to maximize each person’s recovery potential.
Oren Schneider, Co-founder and Chief Executive Officer of Indoma, said, “Hospital discharge is a milestone, not the end of the rehabilitation journey. That conviction is reflected in our name, drawing on the word ‘indomitable’ and the determination to keep moving forward in the face of adversity. We built Indoma to give patients and families a clear path forward when the next step is uncertain. Our focus on patient care drives us to look towards the future of medical technologies as well as to offer each patient the most appropriate and effective treatment currently available - the UAE’s record of translating ambition into action makes it a natural place for the next stage of our growth.”
Dr. Teo Forcht Dagi, Neurosurgeon, and Chairman and Chief Medical Officer of Indoma, said, “The science of neuroplasticity shows that the brain's capacity to recover is not fixed, but can be activated and enhanced by high-frequency, high-intensity, repetitive input and consistent delivery - provided therapy is delivered at sufficient intensity and duration. Each element of Indoma’s practice demonstrates our role in harnessing a patient’s neuroplasticity: the intensity of therapy, the technologies we select, the home setting, the holistic support, and the duration of care. In the UAE, we intend to work as colleagues to the neurologists, neurosurgeons, and rehabilitation physicians already caring for these patients, and to uphold ourselves to the clinical governance expected of any academic center.”
Leading clinical delivery in Dubai will be Dr. Nazakat Hussain, Indoma’s UAE Medical Director, a locally based Consultant in Physical Medicine and Rehabilitation with over 30 years of experience across the UK and UAE, while also serving as Director of the Spinal Cord Injury Program and Clinical Lead for Neurorehabilitation at Specialized Rehabilitation Hospital (SRH) in Abu Dhabi. Joining him will be Dr. Dagi, who holds appointments as Professor of Neurosurgery at the Mayo Clinic College of Medicine and Science, and provides global medical leadership and clinical governance across all Indoma markets.
Indoma will complement the country’s existing healthcare ecosystem by building clinical and referral relationships with physicians, hospitals, and rehabilitation partners, while working alongside the medical teams that patients already know and trust. The service will begin accepting patients through referral or by direct enquiry in the coming weeks.
-ENDS-
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment